MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1.
In Vitro
MLK-IN-1 (100 nM; pre-treatment 20 mins HIV-1 Tat) promotes continued axonogenesis in the presence of Tat-activated microglia and protects against effects of HIV-Tat in vitro. MCE has not independently confirmed the accuracy of these methods. They are for reference only.